Compare Medpace Holdings Inc (MEDP) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Tesla, Inc. — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Tesla, Inc. trades at $382.7 (market cap $1.48T). The key difference: Tesla, Inc. is far larger — about 88× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Tesla, Inc. for 88 Days on average.
| MEDP | TSLA | |
|---|---|---|
Market Cap | $16.82B | $1.48T |
Volume | 223,093 | 28,215,427 |
Sector | Health | Consumer Cyclical |
52-Week High | $630.19 | $489.88 |
52-Week Low | $393.42 | $298.16 |
Typical Hold Time | 14 Days | 88 Days |
Enterprise Value | $16.44B | $1.45T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Tesla (TSLA) trades at $375.03, down 0.68% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported mixed earnings, beating in Q4 2025 and Q1 2026 but missing in Q2 2026, with revenue at $94.83B in 2025 and a net income margin of 4%. Analyst consensus is a Buy with a $441.36 price target, and recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV launch.
Tesla's outlook balances innovation in autonomy and energy against near-term execution risks and high valuation multiples. The stock offers growth potential from AI and robotics expansion, but faces headwinds from competitive pressures and margin compression. Investors should weigh long-term disruptive potential against current profitability challenges and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
